Globus Medical (GMED)

Executive Summary

Globus Medical is a leading musculoskeletal device company specializing in innovative spine and orthopedic solutions. With a strong portfolio of procedurally integrated implants and enabling technologies, including the ExcelsiusGPS robotic navigation system, the company has established itself as a key player in the $50B+ global spine market. Following its transformative acquisition of NuVasive in 2023, Globus Medical has become the second-largest pure-play spine company, with enhanced scale, product breadth, and distribution capabilities. The combination is expected to generate significant cost synergies and cross-selling opportunities, driving margin expansion and revenue growth. As the healthcare industry increasingly adopts minimally invasive and robotic-assisted surgeries, Globus Medical's focus on technology-driven differentiation positions it well for sustained outperformance. The company's commitment to innovation and surgeon education underpins its competitive advantage, while its strong balance sheet enables continued investment in R&D and strategic M&A. Despite near-term integration risks and competitive pressure from Medtronic and others, the long-term outlook remains favorable, supported by favorable demographics and an aging population. We assign a conviction score of 80, reflecting confidence in the company's market leadership and growth trajectory.

Upcoming Catalysts (preview)

• H2 2026NuVasive integration milestones and synergy realization75% success
• H1 2027FDA clearance for next-generation robotic-assisted surgery platform60% success
• Q4 2026Launch of new interbody fusion devices with 3D-printed technology70% success